AmbroSpray has received regulatory approval from China's NMPA
1
AmbroSpray received regulatory approval from China NMPA.
Gogolox® (Ambroxol Hydrochloride Oral Spray) has received regulatory approval from China's NMPA as a Class 5.1 drug! Key Benefits:l High Potency (5%): Strongest Ambroxol concentration on the market.
l Accurate & Fast Delivery: Direct oral spray ensures rapid action and easy administration.
l No Swallowing Required: Ideal for elderly, children, and bedridden patients. Swallowing difficulties affect 37% of adults and 62% of seniors.
l Patient-Friendly Design: Portable, hygienic, and self-administered with a 360° rotating nozzle.
l Clinically Proven & Trusted: Registered in 10+ EU countries (e.g. Germany, Italy, Poland, Portugal) with bioequivalence to Mucosolvan® and superior compliance.
l Real-World Use: Effective across perioperative care (40%), special populations like bedridden patients (30%), and respiratory patients with thick sputum (30%).
